Unknown

Dataset Information

0

Transient HIV-1 Gag-protease interactions revealed by paramagnetic NMR suggest origins of compensatory drug resistance mutations.


ABSTRACT: Cleavage of the group-specific antigen (Gag) polyprotein by HIV-1 protease represents the critical first step in the conversion of immature noninfectious viral particles to mature infectious virions. Selective pressure exerted by HIV-1 protease inhibitors, a mainstay of current anti-HIV-1 therapies, results in the accumulation of drug resistance mutations in both protease and Gag. Surprisingly, a large number of these mutations (known as secondary or compensatory mutations) occur outside the active site of protease or the cleavage sites of Gag (located within intrinsically disordered linkers connecting the globular domains of Gag to one another), suggesting that transient encounter complexes involving the globular domains of Gag may play a role in guiding and facilitating access of the protease to the Gag cleavage sites. Here, using large fragments of Gag, as well as catalytically inactive and active variants of protease, we probe the nature of such rare encounter complexes using intermolecular paramagnetic relaxation enhancement, a highly sensitive technique for detecting sparsely populated states. We show that Gag-protease encounter complexes are primarily mediated by interactions between protease and the globular domains of Gag and that the sites of transient interactions are correlated with surface exposed regions that exhibit a high propensity to mutate in the presence of HIV-1 protease inhibitors.

SUBMITTER: Deshmukh L 

PROVIDER: S-EPMC5098610 | biostudies-literature | 2016 Nov

REPOSITORIES: biostudies-literature

altmetric image

Publications

Transient HIV-1 Gag-protease interactions revealed by paramagnetic NMR suggest origins of compensatory drug resistance mutations.

Deshmukh Lalit L   Louis John M JM   Ghirlando Rodolfo R   Clore G Marius GM  

Proceedings of the National Academy of Sciences of the United States of America 20161017 44


Cleavage of the group-specific antigen (Gag) polyprotein by HIV-1 protease represents the critical first step in the conversion of immature noninfectious viral particles to mature infectious virions. Selective pressure exerted by HIV-1 protease inhibitors, a mainstay of current anti-HIV-1 therapies, results in the accumulation of drug resistance mutations in both protease and Gag. Surprisingly, a large number of these mutations (known as secondary or compensatory mutations) occur outside the act  ...[more]

Similar Datasets

| S-EPMC3064441 | biostudies-literature
| S-EPMC4404092 | biostudies-literature
| S-EPMC8087772 | biostudies-literature
| S-EPMC1563819 | biostudies-literature
| S-EPMC8703889 | biostudies-literature
| S-EPMC9088029 | biostudies-literature
| S-EPMC5699096 | biostudies-literature
| S-EPMC2738184 | biostudies-literature
| S-EPMC4844178 | biostudies-literature
| S-EPMC3508000 | biostudies-literature